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Diabetes, Muscles, and the Myth of
Ulysses’ Bow
A
t the end of Homer’s Odyssey, after
20 years of adventurous traveling,
the goddess Athena brings Ulysses
back to Ithaca disguised as an old man.
With little hope for Ulysses’ return, his
faithfulwifePenelopehasreluctantlyagreed
to marry whoever wins a contest using Ul-
ysses’ bow. In spite of his inﬁrmed appear-
ance, Ulysses is the only contestant strong
enough to string the bow and shoot an ar-
row through 12 axe-handles. Thus, the im-
ageofaheroasthe“onlyonewhocanstring
thebow”hasbeenembeddedincivilization
sincebeforethebeginningofwrittenhistory
and suggests that from time immemorial,
people have equated strong muscles with
youth and good health. Thousands of years
later, we are beginning to understand ex-
actly how health and age affect muscle, and
we are now on the cusp of translating that
knowledge into medical research and
practice.
In this issue of Diabetes Care, Park
etal.(1)fromtheHealth,Aging,andBody
Composition Study group report that in
individualsaged70–79years,adiagnosis
of diabetes is associated with accelerated
decline in muscle mass, especially in
women and in subjects with undiagnosed
diabetes. These longitudinal ﬁndings
open an important chapter in our under-
standing of the complications and conse-
quences of diabetes and its effect on
physical function. However, to fully un-
derstand the relevance of these ﬁndings,
weshouldinterprettheminthecontextof
the known effects of age on body compo-
sition and of diabetes on muscle strength
and physical function (2,3).
The aging process is associated with
consistent changes in body composition
in all animal species, from worms to ro-
dents to primates, with few exceptions
(4–6). With increasing age, lean body
massdecreasesandfatmass(andpossibly
connective tissue mass) increases. These
changesarealmostalwaysassociatedwith
a reduction in vitality, expressed as poor
mobility and physical function (7). In hu-
mans, individuals tend to build muscle
mass over the ﬁrst two decades of life,
begin to lose muscle mass and strength
between the third and fourth decade, and
the decline accelerates during the sixth
decade (8). This age trajectory of muscle
mass and function is universal, but the
interindividual heterogeneity in rates of
decline is so striking that some individu-
alsreachextremeagewithlittlefunctional
consequences while others become weak,
disabled, and die decades earlier.
The source of this heterogeneity is
likely a mix of individual genetic factors,
health behaviors, and the effects of discrete
diseases. Behavioral factors have powerful
effects on muscle mass and strength. A sed-
entarystateisbyfarthestrongestriskfactor
for accelerated decline of lean body mass
withaging.Inactivityimpairsthebalanceof
muscle protein synthesis and degradation
andinﬂuencesmuscle-cellregeneration.In-
activity is also a strong predisposing factor
for many chronic diseases. The role of nu-
tritionasabehavioralinﬂuenceonmuscleis
more controversial and has focused mostly
on proteins and antioxidant micronutrients
(9,10).
Recently, many common and dis-
abling chronic diseases have been shown
to be associated with excessive decline in
lean body mass and muscle strength. The
contribution of diabetes, as shown in the
article by Park et al., is perhaps the most
clearly established, although little is un-
derstood about the underlying biological
mechanisms (11). Accelerated loss of
muscle mass now has also been found in
congestive heart failure, obstructive pul-
monary disease, rheumatoid arthritis and
other autoimmune diseases, chronic kid-
ney disease, peripheral artery disease,
cancer, HIV, and many others (12–17).
The relationship between body com-
position, strength, and function is so inti-
mately intertwined with the relationship
between health, aging, and disease that
low muscle mass, increased fat mass, and
poor muscle strength are more robust
predictorsofdisabilityandmortalitythan
factors related to disease diagnosis, dis-
ease severity, or biomarkers (18,19).
While observational studies have docu-
mented the relative magnitudes of risk
among these factors, it is not clear
whether they act via distinct, shared, or
even cumulative biological mechanisms.
Thus, it is possible that each disease acts
through a unique pathophysiologic
mechanism that is superimposed on the
independent process of body composi-
tion change with aging. Alternatively,
multiple diseases and even aging may
share a common mechanism that acceler-
ates the loss of muscle mass. Studies con-
ducted in animal models suggest that
multiple conditions, including experi-
mentally induced diabetes, may share an
underlying regulatory process that is
characterized by the activation of speciﬁc
atrogenes that upregulate protein catabo-
lism (20). It is not yet known whether
atrogenesplayaroleinage-relatedmuscle
impairmentorwhetheranimalmodelsac-
curately reﬂect the process that occurs in
humans. As the search for potential ther-
apeutictargetsaccelerates,itisessentialto
build an understanding of the biological
mechanisms underlying the loss of mus-
cle mass and strength that can integrate
the contributions of aging, behavior, and
disease. Interestingly—and particularly rel-
evant here—the biological pathways that
modulate the expression of the atrogenes
are strongly affected by the IGF-I/insulin
signaling pathway that has been shown to
inﬂuenceage-relatedchangesinbodycom-
position, strength, and disability.
To add to the complexity of the is-
sues, there is more to muscle strength
than just muscle mass. There is strong ev-
idence in the literature that the decline in
musclestrengththatoccurswithagingre-
sults from a combination of muscle mass
shrinking and the deterioration of muscle
“quality.” Deterioration of muscle quality
appears to be critical. In fact, muscle
strength is a much stronger predictor of
disability and mortality than muscle mass
(19).Wearejustbeginningtoexplorethe
multiple additional factors that affect
muscle quality, including intracellular in-
ﬂuences on energy metabolism and inter-
faces with critical systems such as the
neuromuscular junction (21). The biologi-
cal pathways that affect muscle mass and
quality have both distinct and shared com-
ponents that likely inﬂuence each other.
The ﬁndings reported by Park et al.
lead to exciting new questions: Does op-
timalglycemiccontrolindiabeticpatients
prevent the loss of muscle mass and
strength?Thispossibilityisimpliedinthe
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pared with diagnosed diabetes, is a stron-
ger predictor of the accelerated decline of
muscle mass. Does loss of mass and
strength affect the clinical evolution and
prognosisofdiabetes?Shouldinterventions
to prevent loss of mass and strength in dia-
betes be similar to those used in the general
population such as behavioral strategies
that promote physical activity, or do they
also require a disease-speciﬁc component?
We simply do not have enough data to re-
spond to these questions. Real clinical ben-
eﬁt will require us to link pathophysiology
andmolecularmechanismswithclinicaldi-
agnosisandtreatment.Tounderstandwhat
is happening, we need new, in vivo mea-
suresofmuscleproteinmetabolismthatcan
be repeated over time in well-characterized
patient populations. We also must identify
the signaling pathways that modulate pro-
tein anabolism and catabolism and muscle-
cell differentiation in the presence of
relevant pathologic conditions, as well as
behavioral states such as physical activity
during the aging process.
Finally, the work by Park et al. leads
ustoconsidertheneedforascreeningtest
for the accelerated loss of muscle mass
and strength as a component of good di-
abetic care. Surprisingly, we still do not
know what criteria to use to detect the
problemorhowtobestimplementsucha
screening. There are not yet standard,
population-based normative data on
muscle strength and muscle mass. While
longitudinal studies of multiple popula-
tions have reported on muscle strength
and muscle mass, they have not shared
similar measurement technology or oper-
ationaldeﬁnitions.Inthecaseofdiabetes,
databasesonbodycomposition,strength,
and function in large clinical series of pa-
tientsaregreatlyneededandmightbefea-
sibleancillarystudiestothemanyexisting
multicenter observational and interven-
tion programs. Since muscle mass may be
only one important indicator of the prob-
lem,musclestrengthisprobablythemost
relevant clinical indicator. In patients
who screen positive for “low strength,”
it would be important to determine
whether this condition is attributable to a
reductioninmass,adeteriorationofmus-
cle quality, or a combination of both. Un-
derstanding whether diabetes primarily
affects muscle mass, muscle quality, or
both is a ﬁrst step in understanding the
pathophysiologyofdiabeticmuscleimpair-
ment. Research within the ﬁeld of diabetes
could lead the way and serve as the model
for the many other disease, behavioral, and
age-related factors that affect muscle.
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